engleski

Do laboratories follow heart failure recommendations and guidelines and did we improve? The CARdiac MArker Guideline Uptake in Europe (CARMAGUE)

Background: Natriuretic peptides (NP) are well- established markers of heart failure (HF). During the past 5 years, analyticaland clinical recommendations for measurement ofthese biomarkers have been published in guidelines. The aim of this follow-up survey was to investigate how wellthese guidelines for measurement of NP have been implemented in laboratory practice in Europe.Methods: Member societies of the European Federation of Clinical Chemistry and Laboratory Medicine were invited in 2009 to participate in a web-based audit questionnaire. The questionnaire requested information on type of tests performed, decision limits for HF, turn-around time and frequency of testing. Results: There was a moderate increase (12%) of laboratories measuring NP compared to the initial survey in 2006. The most frequently used HF decision limits for B-type NP (BNP) and N-terminal BNP (NT-proBNP) were, respectively, 100 ng/L and 125 ng/L, derived from the package inserts in 55%. Fifty laboratories used a second decision limit. Age or gender dependent decision limits were applied in 10% (8.5% in 2006). The vast majority of laboratories (80%) did not have any criteria regarding frequency of testing, compared to 33% in 2006. Conclusions: The implementation of NP measurement for HF management was a slow process between 2006 and 2009 at a time when guidelines had just been established. The decision limits were derived from package insert information and literature. There was great uncertainty concerning frequency of testing which may reflect the debate about the biological variability which was not published for most of the assays in 2009.

B-type natriuretic peptide ; follow-up ; guideline implementation ; heart failure ; natriuretic peptides ; N-terminal B-type natriuretic peptide (NT-proBNP).

nije evidentirano